Table 7.
Patient’s characteristics of the OIT-OMB treated group.
| No | G | Age | History of LTE | SCD** at baseline (mL) | SCD** at weeks 8 (mL) | SCD** at weeks 32 (mL) | Total IgE (IU/mL) | CM- sIgE (kUA/L) | OMB (mg) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 13 | No | 1.8 | 87 | 200 | 5164 | 54.4 | 525 |
| 2 | M | 9 | No | 0.8 | 88 | 200 | 1152 | 24 | 300 |
| 3 | M | 7 | Yes (2)* | 1.8 | 17 | 200 | 4316 | 157 | 300 |
| 4 | F | 8 | Yes (1)* | 0.8 | 0 | 45 | 1336 | 2040 | 375 |
| 5 | F | 10 | No | 3.8 | 15 | 200 | 42990 | 75 | 375 |
| 6 | M | 12 | Yes (1)* | 3.8 | 35 | 105 | 1553 | 38.9 | 375 |
| 7 | M | 9 | Yes (1)* | 1.8 | 37 | 105 | 578 | 95 | 300 |
| 8 | M | 10 | No | 0 | 18.8 | 200 | 3521 | 307 | 375 |
| 9 | F | 10 | Yes (3)* | 0.8 | 38 | 200 | 2433 | 40.2 | 375 |
| 10 | F | 8 | No | 1.8 | 37 | 200 | 1024 | 133 | 300 |
OIT: oral immunotherapy, OMB: omalizumab, G: gender, LTE: life threatening event, SCD: successfully consume dose, CM-sIgE: cow’s milk specific IgE, M: male, F: female, *Frequencies of LTE including hypotension. **Fresh CM open food challenge at baseline, weeks 8 and 32.